Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, Gross-Goupil M, Ladoire S, Borchiellini D, Geoffrois L, Joly F, Priou F, Barthelemy P, Laramas M, Narciso B, Thiery-Vuillemin A, Berdah JF, Ferrari V, Dominique Thomas Q, Mione C, Curcio H, Oudard S, Tantot F, Escudier B, Chabaud S, Albiges L, Thibault C. Velev M, et al. Among authors: laguerre b. Eur J Cancer. 2023 Mar;182:66-76. doi: 10.1016/j.ejca.2022.12.028. Epub 2023 Jan 13. Eur J Cancer. 2023. PMID: 36746010 Clinical Trial.
[Standards, Options: Recommendations for the management of patients with epithelial ovarian cancer. Medical front-line treatment (summary report, update 2008)].
Fédération nationale des centres de lutte contre le cancer (FNCLCC). Fédération nationale des centres de lutte contre le cancer (FNCLCC). Gynecol Obstet Fertil. 2008 Jun;36(6):684-700. doi: 10.1016/j.gyobfe.2008.04.009. Epub 2008 Jun 9. Gynecol Obstet Fertil. 2008. PMID: 18539509 Review. French.
Population pharmacokinetics of topotecan: intraindividual variability in total drug.
Montazeri A, Boucaud M, Lokiec F, Pinguet F, Culine S, Déporte-Féty R, Albin N, Laguerre B, Goupil A, Bugat R, Canal P, Chatelut E. Montazeri A, et al. Among authors: laguerre b. Cancer Chemother Pharmacol. 2000;46(5):375-81. doi: 10.1007/s002800000161. Cancer Chemother Pharmacol. 2000. PMID: 11127941 Clinical Trial.
Individual adaptive dosing of topotecan in ovarian cancer.
Montazeri A, Culine S, Laguerre B, Pinguet F, Lokiec F, Albin N, Goupil A, Déporte-Féty R, Bugat R, Canal P, Chatelut E. Montazeri A, et al. Among authors: laguerre b. Clin Cancer Res. 2002 Feb;8(2):394-9. Clin Cancer Res. 2002. PMID: 11839654 Clinical Trial.
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
Négrier S, Gravis G, Pérol D, Chevreau C, Delva R, Bay JO, Blanc E, Ferlay C, Geoffrois L, Rolland F, Legouffe E, Sevin E, Laguerre B, Escudier B. Négrier S, et al. Among authors: laguerre b. Lancet Oncol. 2011 Jul;12(7):673-80. doi: 10.1016/S1470-2045(11)70124-3. Epub 2011 Jun 12. Lancet Oncol. 2011. PMID: 21664867 Clinical Trial.
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
Fizazi K, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houedé N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Lagrange JL, Chinet-Charrot P, Linassier C, Deplanque G, Beuzeboc P, Geneve J, Davin JL, Tournay E, Culine S. Fizazi K, et al. Among authors: laguerre b. Eur J Cancer. 2012 Jan;48(2):209-17. doi: 10.1016/j.ejca.2011.10.015. Epub 2011 Nov 24. Eur J Cancer. 2012. PMID: 22119204 Clinical Trial.
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, Duclos B, Geoffrois L, Rolland F, Guillot A, Laguerre B, Legouffe E, Kohser F, Dietrich PY, Theodore CA, Escudier B. Albiges L, et al. Among authors: laguerre b. J Clin Oncol. 2012 Feb 10;30(5):482-7. doi: 10.1200/JCO.2011.37.2516. Epub 2012 Jan 9. J Clin Oncol. 2012. PMID: 22231040
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M. Gravis G, et al. Among authors: laguerre b. Lancet Oncol. 2013 Feb;14(2):149-58. doi: 10.1016/S1470-2045(12)70560-0. Epub 2013 Jan 8. Lancet Oncol. 2013. PMID: 23306100 Clinical Trial.
124 results